Publication
Article
Pharmacy Times
PRODUCT news
Ciclopirox Gel, 0.77%
Marketed by:
Paddock Laboratories Inc (Minneapolis, MN)
Indication:
December 2007?Paddock Laboratories announced the introduction of Ciclopirox Gel, 0.77%, the first generic now available. It is indicated for the topical treatment of superficial dermatophyte infections?interdigital tinea pedis and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floc-cosum. Ciclopirox Gel also is indicated for the topical treatment of seborrheic dermatitis of the scalp. It is contraindicated in individuals who have shown hypersensitivity to any of its components and is not for ophthalmic, oral, or intravaginal use.
Dosage Form:
Gel: 30-, 45-, and 100-g tubes
For More Information:
800-328-5113
Granisetron Hydrochloride Tablets, 1 mg
Marketed by:
Roxane Laboratories Inc (Columbus, OH)
Compared to:
KYTRIL Tablets (Roche Pharmaceuticals)
Indication:
January 2,2008?Roxane Laboratories announced FDA approval for its abbreviated new drug application for Granisetron Hydrochloride Tablets, 1 mg. Granisetron Hydrochloride Tablets are AB-rated to KYTRIL Tablets. The tablets are indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including a high-dose cisplatin, as well as nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. Granisetron Hydrochloride Tablets are contraindicated in patients with known hypersensitivity to the drug or any of its components.
Dosage Form:
Tablets: 1 mg
For More Information:
800-962-8364
Alendronate Sodium Tablets
Marketed by:
Teva Pharmaceuticals (North Wales, PA)
Compared to:
Fosamax Tablets (Merck & Co Inc)
Indication:
February 6,2008?Teva Pharmaceuticals announced the introduction and availability of Alendronate Sodium Tablets. This product is AB-rated and bioequiv-alent to Fosamax Tablets. Alendronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women; treatment to increase bone mass in men with osteoporosis; treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density; and treatment of Paget?s disease of bone in men and women.
Dosage Form:
Tablets: 5,10,35,40, and 70 mg
For More Information:
Estradiol Valerate
Marketed by:
Sandoz Inc (Princeton, NJ)
Compared to:
Delestrogen (King Pharmaceuticals)
Indication:
October 4, 2007?Sandoz Inc introduced estradiol valerate, a generic equivalent of Delestrogen injections, in'the United States. Estradiol valerate is a female estrogen hormone indicated in the treatment of moderate-to-severe vasomotor symptoms associated with menopause; treatment of moderate-to-severe symptoms of vulvar and vaginal atrophy associated with menopause; treatment of hypoestro-genism due to hypogonadism, castration, or primary ovarian failure; and treatment of advanced andro-gen-dependent carcinoma of the prostate.
Dosage Form:
10-, 20-, and 40-mg vials
For More Information:
